Patient Guide: A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 217 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05552976
Status: 🟢 Enrolling Now
Condition: Relapsed or Refractory Multiple Myeloma
Phase: PHASE3

Where You Can Participate

This study is available at 217 locations across the country.

Top locations include:
  • • Mobile, Alabama
  • • Cerritos, California
  • • Irvine, California
  • • And 214 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) - Join Clinical Trial NCTNCT05552976

How to Join This Clinical Trial - NCTNCT05552976

Learn how to participate in this PHASE3 trial studying an investigational therapy for Relapsed or Refractory Multiple Myeloma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed or Refractory Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed or Refractory Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05552976 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 217 locations. Find a study site near you:

Clinical Research Site

Mobile, Alabama 36604 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Cerritos, California 90703 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Irvine, California 92618 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Los Angeles, California 90017 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Santa Rosa, California 95403 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Stockton, California 95204 - United States

Status: COMPLETED

Clinical Research Site

Newark, Delaware 19713 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Fort Myers, Florida 33901 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Saint Petersburg, Florida 33705 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

West Palm Beach, Florida 33401 - United States

Status: ACTIVE_NOT_RECRUITING

And 207 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Relapsed or Refractory Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships